We described the selection of a novel nucleic acid antibody-like prostate cancer (PCa) that specifically binds to the single-stranded DNA molecule from a 277-nt fragment that may have been partially paired and bound to the PCA3 RNA conformational structure.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PCA3-277 aptamer ligands were obtained, and the best binding molecule, named CG3, was synthesized for validation. Aiming to prove its diagnostic utility, we used an apta-qPCR assay with CG3-aptamer conjugated to magnetic beads to capture PCA3 transcripts, which were amplified 97-fold and 7-fold higher than conventional qPCR in blood and tissue, respectively. Histopathologic analysis of 161 prostate biopsies arranged in a TMA and marked with biotin-labeled CG3-aptamer showed moderate staining in both cytoplasm and nucleus of PCa samples; in contrast, benign prostatic hyperplasia (BPH) samples presented strong nuclear staining (78% of the cases). No staining was observed in stromal cells.
In addition, using an apta-qPCR, we demonstrated that CG3-aptamer specifically recognizes the conformational PCA3-277 molecule and at least three other transcript variants, indicating that long non-coding RNA (lncRNA) is processed after transcription. We suggest that CG3-aptamer may be a useful PCa diagnostic tool. In addition, this molecule may be used in drug design and drug delivery for PCa therapy.
Sci Rep. 2015 Jul 15;5:12090. doi: 10.1038/srep12090.
Marangoni K1, Neves AF2, Rocha RM3, Faria PR4, Alves PT5, Souza AG5, Fujimura PT5, Santos FA5, Araújo TG5, Ward LS6, Goulart LR7.
1 1] Laboratory of Cancer Molecular Genetics, Faculty of Medical Sciences, State University of Campinas, SP, Brazil  Laboratory of Nanobiotechnology, Institute of Genetics and Biochemistry, Federal University of Uberlândia, MG, Brazil.
2 Laboratory of Molecular Biology, Institute of Biotechnology, Federal University of Goiás, Catalão/GO, Brazil.
3 AC Camargo Cancer Hospital, SP, Brazil.
4 Laboratory of Histology, Institute of Biomedical Sciences, Federal University of Uberlândia, MG, Brazil.
5 Laboratory of Nanobiotechnology, Institute of Genetics and Biochemistry, Federal University of Uberlândia, MG, Brazil.
6 Laboratory of Cancer Molecular Genetics, Faculty of Medical Sciences, State University of Campinas, SP, Brazil.
7 1] Laboratory of Nanobiotechnology, Institute of Genetics and Biochemistry, Federal University of Uberlândia, MG, Brazil  University of California-Davis, Dept. of Medical Microbiology and Immunology, Davis/CA, USA.